South Africa is moving to expand domestic production of a locally developed foot-and-mouth disease vaccine, with qualifying private companies now able to participate in manufacturing under conditional licensing arrangements with the Agricultural Research Council.
The development could become an important step in strengthening livestock disease control and increasing the country’s ability to respond to outbreaks.
On 21 September 2026, Agriculture Minister Willie Aucamp announced that the Agricultural Research Council (ARC) and its board had unanimously approved a proposal allowing qualifying private companies to use the ARC’s intellectual property to manufacture its foot-and-mouth disease (FMD) vaccine at larger scale.
The decision comes as South Africa continues to manage the effects of FMD on livestock producers, animal movement and agricultural supply chains.
Why vaccine production capacity matters
The ARC vaccine has been developed as a defence against domestic FMD strains and requires a single annual administration, according to the Department of Agriculture.
However, the ARC has faced manufacturing constraints that have prevented the vaccine from being produced at the scale required.
The new approach is intended to address that bottleneck.
Under conditional intellectual-property licensing agreements with the ARC, qualifying local and international companies will be allowed to manufacture the vaccine while the research council continues strengthening its own manufacturing capacity.
For livestock farmers, the importance of this development lies not only in the vaccine itself but in the potential to improve availability.
Disease outbreaks can have consequences well beyond individual farms. Restrictions on animal movement can disrupt markets, auctions, feedlot operations, abattoirs and other parts of the livestock value chain.
The ability to respond more effectively therefore has implications for producers, traders, processors and the broader food supply chain.
From research to commercial-scale production
The ARC’s involvement is particularly significant because it links South Africa’s public agricultural research capability with private-sector manufacturing capacity.
The arrangement is designed to allow companies with the necessary capabilities to participate in production without removing the ARC’s role in the vaccine’s underlying intellectual property.
The Department of Agriculture described the partnership as an opportunity to overcome manufacturing limitations and strengthen national biosecurity.
The model also demonstrates how public research and private investment can potentially work together when agricultural challenges require production capacity beyond what a public institution can immediately provide.
What FMD means for livestock businesses
Foot-and-mouth disease is a highly contagious animal disease affecting cloven-hoofed animals, including cattle, sheep, goats and pigs.
For commercial livestock producers, disease management involves more than vaccination. Biosecurity, animal movement controls, surveillance, veterinary services and rapid reporting all remain important components of disease prevention and control.
The availability of vaccines can nevertheless strengthen the overall response by providing an additional tool for protecting susceptible livestock.
The government’s announcement therefore comes at a time when livestock producers are watching developments around disease control closely.
The Western Cape, for example, has been implementing a provincial vaccination programme. Government reported earlier in September that approximately 82% of the province’s cattle herd had received primary FMD vaccination, while booster vaccination was also progressing.
Implications for the agricultural value chain
FMD control has implications far beyond cattle farms.
When animal diseases affect movement and trade, the consequences can extend to livestock markets, meat processors, transport operators, feed suppliers and rural communities whose businesses depend on agricultural activity.
Improved vaccine availability could therefore contribute to greater resilience across the livestock value chain, although vaccination is only one part of the wider disease-management system.
For agricultural businesses, the development also highlights an expanding market for veterinary services, cold-chain systems, animal-health monitoring, diagnostic technologies, biosecurity products and specialised logistics.
Companies operating in these areas could increasingly find themselves participating in a broader agricultural-health ecosystem rather than a narrow livestock market.
A potential boost for agricultural biosecurity
The decision to involve private manufacturers also reflects the scale of the challenge facing South Africa’s livestock industry.
The government has said that allowing additional manufacturers to produce the ARC vaccine should help overcome current production constraints while expanding availability.
Minister Aucamp described the partnership between government research and the private sector as an important step towards protecting livestock, strengthening biosecurity and securing food supply chains.
The next stage will be implementation: identifying qualifying manufacturers, establishing licensing arrangements, scaling production and ensuring that vaccines can reach producers efficiently.
For farmers, the value of the announcement will ultimately be measured by practical outcomes — availability, accessibility and the ability to support effective disease-control programmes on the ground.
Why this matters now
South Africa’s livestock industry is an important contributor to rural economies, food production and agricultural employment. Protecting animal health is therefore directly connected to protecting the wider agricultural economy.
The decision to open the ARC’s FMD vaccine technology to additional manufacturers represents a significant change in the country’s approach to vaccine-production capacity.
It does not remove the need for farmers to maintain strong biosecurity or follow veterinary guidance. Instead, it adds another component to the country’s broader disease-control response.
For livestock producers, the development will be watched closely as South Africa works to strengthen its ability to respond to FMD and protect the movement of animals and agricultural products.
The bigger story is about capacity: building an agricultural system capable of producing critical animal-health products locally, involving private-sector expertise and responding faster when disease threatens the livestock economy.
